FDA grants Breakthrough Therapy Designation for elsunersen in rare pediatric epilepsy

Filed June 22, 2026 · Period ending June 22, 2026 · ~1 min read

Key Changes

• high

  FDA granted Breakthrough Therapy Designation for elsunersen (PRAX-222) to treat seizures in SCN2A-DEE, a rare pediatric epilepsy, based on Phase 1/2 trial results showing substantial improvement potential over existing treatments.

  Item 8.01 verify on EDGAR →
• high

  The designation enables faster development and regulatory review, potentially accelerating time to market for the company's lead drug candidate.

  Item 8.01 verify on EDGAR →
• high

  BTD was supported by positive topline results from EMBRAVE Part A, a sham-controlled Phase 1/2 study in nine pediatric patients aged 2-12 years with early-seizure-onset SCN2A-DEE.

  Item 8.01 verify on EDGAR →